POPNEXT• Intercontinental Survey •

Patterns Of Practice in NASH and EXpectations for Therapies

• POP NEXT Steering committee members •

Pr Quentin ANSTEE, UKDr Salvador AUGUSTIN, SpainPr Elisabetta BUGIANESI, ItalyPr Liana GHEORGHE, Romania

Pr Vlad RATZIU, FranceDr Nancy REAU, USA

Dr Jörn SCHATTENBERG, GermanyPr Vincent WONG, Hong Kong

Participate in the POP NEXT Survey before end of February 2020!

This project was undertaken in collaboration with, and funded by, Intercept Pharma Europe Limited. Questionnaire content and editorial control of any related publications has throughout been with the project steering committee.

POPNEXT• Intercontinental Survey •

• POP NEXT •

Non-alcoholic steatohepatitis (NASH), characterized by steatosis, lobular inflammation, fibrosis and hepato-cellular ballooning, is set to become the leading cause of liver transplantation in the US, in the upcoming years.The Patterns of Practice in NASH and EXpectations for Therapies (POP NEXT) intercontinental survey aims to publish an expert position paper based on the current and future management of patients with nonalcoholic steatohepatitis.

This intercontinental survey involves liver specialists from 8 countries: France, Germany, Hong Kong, Italy, Romania, Spain, UK and USA in order to obtain a comprehensive understanding of NASH management, taking account of the diversity of the disease and health care systems.

We would value your professional experience to answer an online questionnaire covering fields from diagnosis to expectations for future treatments to come.To participate, simply click on the link provided in the e-mail you will receive or flash the QR code below. Your time in completing the survey will be compensated, according to your local code.The anonymised results will be analysed and reported in aggregate only, and all responses will be completely confidential. The Steering Committee thank you for your kind involvement and your precious contribution to this project, which has the potential to improve knowledge and future practice in NASH management.

This project was undertaken in collaboration with, and funded by, Intercept Pharma Europe Limited. Questionnaire content and editorial control of any related publications has throughout been with the project steering committee

www.popnextsurvey.com

Please answer the survey before end of February 2020!